Hydrogenation of cyclic ketones

The hydrogenation process addresses inefficiencies in cyclobutanone derivative synthesis by reducing waste and expanding product diversity, offering an environmentally friendly and selective route to cyclobutanone and cyclobutane derivatives.

WO2024231436A1PCT designated stage expired Publication Date: 2024-11-14ARXADA AG
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/062693
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for synthesizing cyclobutanone derivatives are inefficient due to significant zinc waste generation and limited production of functionalized cyclobutenone derivatives, necessitating an optimized and environmentally friendly process.

Method used

A process involving the hydrogenation of specific compounds under controlled conditions, using a catalyst, to produce cyclobutanone derivatives with reduced waste and increased functional group flexibility, allowing for the synthesis of various compounds including cyclobutanone and cyclobutane derivatives.

Benefits of technology

The process provides a flexible, efficient, and environmentally friendly route to cyclobutanone derivatives, reducing waste and enabling the production of diverse compounds with controlled selectivity, including cis/trans isomers, thus overcoming the limitations of existing methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000003_0001
    Figure IMGF000003_0001
Patent Text Reader

Abstract

The present invention relates to the hydrogenation of cyclic ketones such as a process for the preparation of cyclobutanone derivatives and of cyclobutane derivatives. The invention further relates to specific cyclobutanone derivatives.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] HYDROGENATION OF CYCLIC KETONES

[0002] Technical Field

[0003] The present invention relates to the hydrogenation of cyclic ketones such as a process for the preparation of cyclobutanone derivatives and of cyclobutane derivatives. The invention further relates to specific cyclobutanone derivatives.

[0004] Functionalized cyclobutanone derivatives are valuable intermediates for the production of various compounds such as pharmaceutical and agrochemical agents. An example of such functionalized cyclobutanone derivatives is 3-acetoxy-cyclobutan-1-one.

[0005] 3-Acetoxy-cyclobutan-1-one is commonly synthesized in a two-step reaction as described in Dehmlow, E.V. and Biiker, S., “Stereoselektive Synthese von 3-substituierten Cyclobutanolen und Folgeprodukten”, Chem. Ber., 1993, 126, p. 2759-2763, which proceeds via a three-step process presented on the following reaction scheme:

[0006] Inter alia, this process however suffers from the drawback associated to the generation of a significant amount of zinc waste, which makes this synthetic pathway economically and ecologically inefficient.

[0007] CH 596 132 discloses a process for the preparation of 3-acetoxy-cyclobutan-1-one via the hydrogenation of 3-acetoxy-2-cyclobuten-1-one (also known as triketene). Triketene is a side product in the diketene (4-methyleneoxetan-2-one) production. Triketene can be obtained from the distillation residue collected in the diketene production. The distillation residue from the diketene production, which is also referred to as triketene resin, typically comprises 10% diketene, 30% triketene and 60% undefined compounds. However, the method disclosed in CH 596 132 suffers inter alia from the draw-back that only triketene (3-acetoxy-2-cyclobuten-1-one) and no other functionalized cyclobutenone derivatives can be obtained.

[0008] US 2017 / 0334815 relates to hydrogenation of substituted 1 ,3-cyclobutanediketone compounds.

[0009] Hence, there is an ongoing need for optimized processes for the synthesis of cyclobutanone derivatives and cyclobutane derivatives.

[0010] An object of the present invention is to provide a straightforward process for the synthesis of cyclobutanone derivatives and cyclobutane derivatives. A further object of the present invention is to provide an efficient and / or environmentally friendly (e.g., cutback of starting materials costs and waste reduction) process for the synthesis of cyclobutanone derivatives and cyclobutane derivatives. A further object of the present invention is to efficiently provide novel cyclobutanone derivatives of economic interest.

[0011] Summary of the invention

[0012] In one aspect, the present invention provides a process for the preparation of a compound of formula (1) wherein

[0013] R1is H, -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12,-O-SiR13R14R15, or -

[0014] NRBRC;

[0015] R2and R3represent =O or

[0016] R2is -OH or -NRBRcand R3is H;

[0017] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0018] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0019] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0020] RAis H or optionally substituted C1-12 alkyl;

[0021] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0022] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0023] X is O, S, or NH; the process comprising reacting a compound of formula (2) wherein

[0024] RX1and RX4represent =O or -S-C2-6 alkylene-S- and RX5is H, or

[0025] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;

[0026] RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;

[0027] RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD;

[0028] RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0029] RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0030] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;

[0031] RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; and RXE(+)is a cation; with hydrogen.

[0032] In another aspect, the present invention provides a process for the preparation of a compound of formula (1) wherein

[0033] R1is -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12,-O-SiR13R14R15, or -NRBRc;

[0034] R2and R3represent =O or

[0035] R2is -OH or -NRBRcand R3is H;

[0036] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0037] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0038] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0039] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0040] RAis H or optionally substituted C1-12 alkyl;

[0041] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0042] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0043] X is O, S, or NH; the process comprising reacting a compound of formula (2) wherein

[0044] RX1and RX4represent =O and RX5is H, or

[0045] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;

[0046] RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;

[0047] RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD;

[0048] RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0049] RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0050] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;

[0051] RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; and

[0052] RXE(+)is a cation; with hydrogen, wherein the compound of formula (2) is reacted with hydrogen in the presence of a catalyst, and wherein reacting the compound of formula (2) with hydrogen is performed at about 5 to about 60 bar hydrogen pressure.

[0053] In a second aspect, the invention relates to a compound of formula (1-1)

[0054] (1-1) wherein

[0055] R1is -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12, -O-SiR13R14R15, or -NRBRc;

[0056] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc; R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0057] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0058] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0059] RAis H or optionally substituted C1-12 alkyl;

[0060] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0061] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0062] X is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl, or benzyl, that -NRA-C(O)-R11is not -NH-C(O)- NH2, and that RDis not tert-butyl.

[0063] In yet another aspect, the invention relates to a compound of formula (1-1)

[0064] (1-1) wherein

[0065] R1is -O-C(O)-R10, -O-C(O)-X-R12, -O-S(O)2-R12, or -NRBRc;

[0066] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0067] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted aryl;

[0068] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0069] X is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl, or benzyl. Detailed description of the invention

[0070] In the following, the invention will be explained in more detail.

[0071] The terms "about" and "approximately" in the context of the present invention denotes an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. The term typically indicates a deviation from the indicated numerical value of ±10% and preferably ±5% such as ±3% or ±2%.

[0072] It needs to be understood that the term "comprising" is not limiting. For the purposes of the present invention, the term "consisting of is considered to be a preferred embodiment of the term "comprising of. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also meant to encompass a group, which preferably consists of these embodiments only.

[0073] According to the present invention, the term “alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 1 to 12 carbon atoms, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. Likewise, the term “C2-6 alkyl” refers to a straight-chained or branched saturated hydrocarbon group having 2 to 6 carbon atoms (i.e. 2, 3, 4, 5, or 6 carbon atoms) including ethyl, propyl, 1 -methylethyl, butyl, 1 -methylpropyl, 2-methylpropyl, 1 , 1 -dimethylethyl, pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1 -ethylpropyl, 1 ,1 -dimethylpropyl,

[0074] 1 .2-dimethylpropyl, hexyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl,

[0075] 1 ,1 -dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl,

[0076] 3.3-dimethylbutyl, 1 -ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethyl propyl, 1 ,2,2-trimethylpropyl, 1-ethyl-1- methylpropyl and 1-ethyl-2-methylpropyl.

[0077] The term “alkylene” as used herein refers to a bivalent linear or branched alkyl group, e.g. -(CH2)x- or -CH(CH3)CH2-, wherein x is a positive integer of usually 1 to 12, preferably 1 to 10 or 1 to 5. In the context of the present invention "C2-6-alkylene" refers to an alkylene moiety with 2, 3, 4, 5, and 6 respectively, carbon atoms, e.g. -CH2- groups; the term "alkylene", however, not only comprises linear alkylene groups, i.e. "alkylene chains", but branched alkylene groups, as well.

[0078] According to the present invention, the term “C3-8 cycloalkyl” refers to monocyclic saturated hydrocarbon radicals having 3 to 8 carbon ring members (i.e. 1 , 2, 3, 4, 5, 6, 7, or 8 carbon atoms) including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Likewise, the term “C3-6 cycloalkyl” refers to monocyclic saturated hydrocarbon radicals having 3 to 6 carbon ring members (i.e. 1 , 2, 3, 4, 5, or 6 carbon atoms) including cyclopropyl, cyclobutyl, cyclopentyl, and cyclo hexyl.

[0079] The term “C3-8 cycloalkenyl” as used herein refers to unsaturated (but not aromatic) carbocyclic compounds that can include one or more rings. Thus, the cyclic moiety comprises at least one C=C double bond. In general and if not defined otherwise in the specification - the moiety has a single point of attachment to the remainder of the molecule, with 3, 4, 5, 6, 7, or 8 ring carbon atoms. Examples of “cycloalkenyl” groups include cyclopropenyl, cyclopropadienyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cyclooctenyl, and bicyclo[2.2.2]octenyl.

[0080] According to the present invention, the term “aryl” refers to refers to both single-ring aromatic hydrocarbyl groups and polycyclic aromatic ring systems (i.e. fulfilling the Hiickel rule - having (4n+n2) electrons, with n being 0 or an integer of preferably 1 to 3). The polycyclic rings may have two or more rings in which two carbons are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is an aromatic hydrocarbyl group, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles, and / or heteroaryls. Preferred aryl groups are those containing six to twelve carbon atoms. Especially preferred is an aryl group having six carbons, ten carbons or twelve carbons. Suitable aryl groups include phenyl, biphenyl, triphenyl, triphenylene, tetraphenylene, naphthalene, anthracene, phenalene, phenanthrene, fluorene, pyrene, chrysene, perylene, and azulene, preferably phenyl, biphenyl, triphenyl, triphenylene, fluorene, and naphthalene.

[0081] The term “alkylaryl” refers to a substituted or unsubstituted aryl moieties linked to the rest of the molecule via a carbon chain. In its easiest form, "alkylaryl" refers to benzyl. Other examples are styryl, phenylethyl, phenylpropyl.

[0082] It is to be understood that the C1-12 alkyl, C2-12 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, aryl, and alkylaryl may optionally be further substituted. Exemplary substituents include hydroxy, linear or branched C1-12 alkyl, C3-8 cycloalkyl, a carbonyl group (C=O), a carboxy group, halogen, and phenyl. In this connection, optionally substituted alkyl suitable encompasses the haloalkyl, wherein the hydrogen atoms of this alkyl group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from Ci-C4-haloalkyl, more preferably from Ci-Cs-haloalkyl or C1-C2- haloalkyl, in particular from Ci-C2-fluoroalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, 1- fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like. The term “optionally substituted” denotes that at least one hydrogen atom (located at a carbon atom or a suitable heteroatom) is replaced with another, suitable substituent, such as halogen, OH; NH2, CN, oxo, C1-6 alkyl, C2-6 alkenyl, C1-6 hydroxyalkyl, C1-6 alkoxy, aryl (e.g. phenyl), alkylaryl (e.g. benzyl), and C3-8 cycloalkyl.

[0083] According to the present invention, the term “halogen” refers to fluorine, chlorine, bromine and iodine.

[0084] As outlined above, subject of the present invention is a process for the preparation of a compound of formula (1)

[0085] R wherein

[0086] R1is H, -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12, -O-SiR13R14R15, or -NRBRc;

[0087] R2and R3represent =O or

[0088] R2is -OH or -NRBRcand R3is H;

[0089] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0090] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0091] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0092] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0093] RAis H or optionally substituted C1-12 alkyl;

[0094] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0095] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0096] X is O, S, or NH; the process comprising reacting a compound of formula (2)

[0097] wherein

[0098] RX1and RX4represent =O or -S-C2-6 alkylene-S- and RX5is H, or

[0099] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;

[0100] RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;

[0101] RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD; RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0102] RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0103] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;

[0104] RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; and RXE(+)is a cation; with hydrogen.

[0105] The inventive process provides an excellent route for the preparation of compounds of formula (1). Particularly, it has been surprisingly found that the inventive process is very flexible regarding functional groups, controllable regarding e.g. selectivity, provides access to various compounds, and is easy to handle. In addition, the inventive process e.g. provides the possibility to introduce cis / trans steric as desired by selective hydrogenation of the alkene / carbonyl.

[0106] It is to be understood that since according to the inventive process the compound of formula (2) is the starting material of the compound of formula (1), that the respective moieties typically correspond so that if e.g. R10is optionally substituted C2-12 alkyl, RX1° is optionally substituted C2-12 alkyl, as well. However, in the event that e.g. R10is optionally substituted C3-8 cycloalkyl, RX1° can be optionally substituted C3-8 cycloalkyl or optionally substituted C3-8 cycloalkenyl.

[0107] In one embodiment, the invention relates to a process for the preparation of a compound of formula (1)

[0108] (1), wherein

[0109] R1is -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12,-O-SiR13R14R15, or -NRBRc;

[0110] R2and R3represent =O or

[0111] R2is -OH or -NRBRcand R3is H;

[0112] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0113] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0114] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0115] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0116] RAis H or optionally substituted C1-12 alkyl;

[0117] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0118] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0119] X is O, S, or NH; the process comprising reacting a compound of formula (2)

[0120] wherein

[0121] RX1and RX4represent =O and RX5is H, or

[0122] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;

[0123] RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;

[0124] RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD;

[0125] RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0126] RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0127] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;

[0128] RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; and

[0129] RXE(+)is a cation; with hydrogen, wherein the compound of formula (2) is reacted with hydrogen in the presence of a catalyst, and wherein reacting the compound of formula (2) with hydrogen is performed at about 5 to about 60 bar hydrogen pressure.

[0130] In one embodiment, R2and R3represent =O so that the compound of formula (1) is a compound of formula (1-1)

[0131] In another embodiment, R2is -OH or -NRBRCand R3is H.

[0132] In one embodiment, R10is optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, or phenyl. In one embodiment, R1is optionally substituted C2-6 alkyl, optionally substituted C3-6 cycloalkyl, or phenyl.

[0133] In one embodiment, R10is ethyl, propyl, 1 -methylethyl, butyl, 1 -methylpropyl, 2-methylpropyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or phenyl.

[0134] Preferably, R10is phenyl.

[0135] In another preferred embodiment, R10is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, phenyl, or -NRBRc.

[0136] In one embodiment, R11is substituted C1-6 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, -NRBRC, or -ORD, preferably -NRBRCor -ORD.

[0137] In one embodiment, R12is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted aryl, preferably is optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, or phenyl.

[0138] In one embodiment, R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl. Suitable “SiR13R14R15“ include SiMe2tBu, SiPti2tBu, and SiiPrs.

[0139] In one embodiment, RAis H or optionally substituted C1-8 alkyl, preferably H or optionally substituted C1-6 alkyl, more preferably H or optionally substituted C1-4 alkyl, still more preferably H or methyl, and in particular H.

[0140] In one embodiment, RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; preferably are independently H, optionally substituted Ci-e alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; more preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl; and in particular are independently H, phenyl, or benzyl; or are independently optionally substituted C3-6 cycloalkyl, phenyl, or benzyl.

[0141] In one embodiment, RBand Rcare the same.

[0142] In another embodiment, RBand Rcare different.

[0143] In one embodiment, RDis optionally substituted C1-10 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, and in particular optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl.

[0144] In one embodiment, the compound of formula (2) is a compound of formula (2-1)

[0145] In one embodiment, the compound of formula (2) is a compound of formula (2-1) wherein RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+). In this connection, it is to be understood that if RX4and RX5together form a bond, the compound of formula (2) is a compound of formula (2-1).

[0146] In one embodiment, the compound of formula (2) is a compound of formula (2-2)

[0147] (2-2), preferably wherein the compound of formula (1) is a compound of formula (1-2)

[0148] (1-2).

[0149] In one embodiment, the compound of formula (2) is a compound of formula (2-1)

[0150] (1-2).

[0151] In one embodiment, the compound of formula (2) is a compound of formula (2-2) wherein RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+). In this connection, it is to be understood that if RX4and RX5are both H, the compound of formula (2) is a compound of formula (2-2).

[0152] In another embodiment,

[0153] RX1and RX4represent =O or -S-C2-6 alkylene-S-, preferably =O or -S-C2-4 alkylene-S-, and in particular =O or -S-CH2-CH2-S-; and

[0154] RX5is H.

[0155] According to one embodiment, the compound of formula (2) is a compound of formula (2-3) or a compound of formula (2-4)

[0156] With regard to the moieties RX1°, RX11, RX12, RX13, RX14, RX15, RXB, Rxc, and RXD, it is to be understood that equal preferred embodiment apply since the compound of formula (2) is the starting material of the compound of formula (1). However, as above-outlined, with regard to e.g. cycloalkyl moieties in the compound of formula (1), the respective moiety in the compound of formula (2) may be the respective cycloalkyl or cycloalkenyl.

[0157] In a preferred embodiment, X is O.

[0158] In one embodiment,

[0159] R1is -O-C(O)-R10;

[0160] R2and R3represent =O;

[0161] R10is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, phenyl, or -NRBRC;

[0162] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl;

[0163] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond; and RX1° is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, tert-butyl, phenyl, or -NRBRc; and

[0164] RXBand Rxcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl.

[0165] In one embodiment,

[0166] R1is -O-C(O)-R10;

[0167] R2and R3represent =O;

[0168] R10is chlorine, -OH, or -NRBRc;

[0169] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl;

[0170] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond; and RX1° is chlorine, -OH, or -NRBRc; and

[0171] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl.

[0172] In one embodiment,

[0173] R1is -O-C(O)-R10;

[0174] R2and R3represent =O;

[0175] R10is -NRBRC;

[0176] RBand Rcare optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably phenyl or benzyl;

[0177] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond; and RX1O-NRBRC; and

[0178] RXBand Rxcare optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are phenyl or benzyl.

[0179] In one embodiment,

[0180] R1is -O-C(O)-R10;

[0181] R2and R3represent =O;

[0182] R10is -NRBRC; RBis H;

[0183] Rcis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is phenyl or benzyl;

[0184] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond; and RX1° is -NRBRC;

[0185] RXBis H; and

[0186] Rxcis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is phenyl or benzyl.

[0187] In one embodiment,

[0188] R1is -O-C(O)-R10;

[0189] R2and R3represent =O;

[0190] R10is optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably is ethyl, 1 -methylethyl, trifluoromethyl, phenyl, benzyl, para-methyl phenyl, or para methylphenylketon;

[0191] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond; and and RX1° is optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably is ethyl, 1 -methylethyl, trifluoromethyl, phenyl, benzyl, para-methyl phenyl, or para methylphenylketon.

[0192] In one embodiment,

[0193] R1is -NRA-C(O)-R11;

[0194] R2and R3represent =O;

[0195] R11is -NRBRcor -ORD;

[0196] RAis H;

[0197] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H or optionally substituted C3-6 cycloalkyl;

[0198] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl;

[0199] RX1is -NRA-C(O)-RX11and RX4and RX5together form a bond;

[0200] RX11is -NRXBRxcor -ORXD; RXBand Rxcare independently selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H, optionally substituted C3-6 cycloalkyl or optionally substituted C3-8 cycloalkenyl; and

[0201] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted

[0202] C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, phenyl, or benzyl.

[0203] In one embodiment,

[0204] R1is -NRA-C(O)-R11;

[0205] R2and R3represent =O;

[0206] R11is -ORD;

[0207] RAis H;

[0208] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl;

[0209] RX1is -NRA-C(O)-RX11and RX4and RX5together form a bond;

[0210] RX11is -ORXD; and

[0211] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted

[0212] C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, phenyl, or benzyl.

[0213] In one embodiment,

[0214] R1is -NRA-C(O)-R11;

[0215] R2and R3represent =O;

[0216] R11is -NRBRc;

[0217] RAis H; and

[0218] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are both H or RBis H and Rcis C3-6 cycloalkyl substituted with carbonyl;

[0219] RX1is -NRA-C(O)-RX11and RX4and RX5together form a bond;

[0220] RX11is -NRXBRxc; and

[0221] RXBand Rxcare independently selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are both H or RXBis H and Rxcis C3-6 cycloalkyl substituted with carbonyl or Cs-s cycloalkenyl substituted with carbonyl.

[0222] In one embodiment,

[0223] R1is -O-C(O)-X-R12, O-S(O)2-R12, or -0-SiR13R14R15;

[0224] R12is optionally substituted C1-6 alkyl or optionally substituted C3-8 cycloalkyl, preferably is optionally substituted C1-4 alkyl or optionally substituted C3-6 cycloalkyl (such as C3-6 cycloalkyl substituted with carbonyl); and

[0225] R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl;

[0226] RX1is -O-C(O)-X-Rx12, O-S(O)2-RX12, or -0-SiRx13Rx14Rx15and RX4and RX5together form a bond;

[0227] RX12is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted C3-8 cycloalkenyl, preferably is optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl (such as C3-6 cycloalkyl substituted with carbonyl), or optionally substituted C3-6 cycloalkenyl (such as C3-6 cycloalkenyl substituted with carbonyl);

[0228] R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl; and

[0229] X is O.

[0230] In one embodiment,

[0231] R1is -OH, -O-C(O)-R10or -NRBRc;

[0232] R2and R3represent =O or

[0233] R2is -OH or -NRBRcand R3is H;

[0234] R10is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl; and

[0235] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl;

[0236] RX1is -O-C(O)-RX1° or -O(_)RXE(+)and RX4and RX5together form a bond;

[0237] RX1° is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl; and RXE(+)is an amine cation. In one embodiment,

[0238] R1is -OH;

[0239] R2is -OH and R3is H;

[0240] RX1is -O( )RXE(+)and RX4and RX5together form a bond; and RXE(+)is an amine cation.

[0241] In one embodiment,

[0242] R1is -NRBRC;

[0243] R2and R3represent =O or

[0244] R2is -OH or -NRBRcand R3is H;

[0245] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl;

[0246] RX1is -O( )RXE(+)and RX4and RX5together form a bond; and RXE(+> |S an amjnecation.

[0247] In one embodiment, the process further comprises adding a compound of formula (3)

[0248] NHRXBRXC(3) wherein RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, and in particular are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl. In this connection, the process further comprises a reductive amination.

[0249] In one embodiment, R1is -O-C(O)-R10; R2is -OH and R3is H;

[0250] R10is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl;

[0251] RX1is -O-C(O)-RX1° and RX4and RX5together form a bond;

[0252] RX1° is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl; and RXE(+)is an amine cation.

[0253] In one embodiment, the cation is an amine cation, preferably is a compound of formula (4)

[0254] [NR20R21R22R23](+)(4) wherein

[0255] R20and R21are independently selected from the group consisting of optionally substituted Ci-Cw- alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or R20and R21together with the N atom to which they are bonded form a 5- to 12-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from N, O, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RF, preferably are independently selected from the group consisting of optionally substituted Ci-Ce-alkyl and optionally substituted C3-8 cycloalkyl;

[0256] R22is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl;

[0257] R23is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl; and

[0258] RFis halogen, -OH, or optionally substituted Ci-Cw-alkyl.

[0259] In a preferred embodiment,

[0260] R20and R21are optionally substituted C3-8 cycloalkyl, preferably C4-6 cycloalkyl;

[0261] R22is H; and

[0262] R23is H.

[0263] In one embodiment, the Cn-malkyl, Cn-malkyl, Cn-mcycloalkyl, Cn-mcycloalkenyl, aryl, and alkylaryl are not further substituted. It is to be understood that the prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group.

[0264] In one embodiment, R1is -OH; R2is -OH and R3is H;

[0265] RX1and RX4represent =O; and RX5is H.

[0266] In a specific embodiment, the hydroxyl groups of R1and R2are cis.

[0267] In one embodiment,

[0268] R1is H;

[0269] R2and R3represent =O;

[0270] RX1and RX4represent -S-C2-6 alkylene-S-, preferably -S-C2-4 alkylene-S-, and in particular -S-CH2- CH2-S-; and

[0271] RX5is H.

[0272] In one embodiment, the compound of formula (2) is reacted with hydrogen in the presence of a catalyst.

[0273] In one embodiment, the catalyst is present in an amount of about 0.5 to about 10 wt%, more preferably of about 1 to about 8 wt%, and in particular of about 3 to about 6 wt% such as about 5 wt%, based on the total amount of the compound of formula (2).

[0274] Any suitable catalyst may be applied.

[0275] In one embodiment, the catalyst is a metal catalyst, preferably platinum or palladium catalyst. Preferably, the catalyst is Pd / C or Pt / C. In this connection, the catalyst such as Pd / C is suitably present in an amount of about 0.5 to about 10 wt%, more preferably of about 1 to about 8 wt%, and in particular of about 3 to about 6 wt% such as about 5 wt%, based on the total amount of the compound of formula (2). These conditions are exemplarily suitable to hydrogenate a double bond, (i.e. to obtain a compound of formula (1-1)).

[0276] In one embodiment, the catalyst is a ruthenium catalyst. Preferably, the catalyst is Ru / C, Ru-Macho- BH (carbonylhydrido(tetrahydroborato)[bis(2-diphenylphosphinoethyl)amino]ruthenium(ll); CAS 1295649-41-0), (R)-RuCI[(p-Cymol)(SEGPHOS®)]CI (Chloro-[(R)-(+)-5,5'-bis-(diphenylphosphino)- 4,4'— bi— 1 ,3-benzodioxol]-(p-cymol)-ruthenium(ll)-chlorid; CAS 944451-28-9), (R)-RuCI[(p- Cymol)(BINAP)]CI (Chloro-[(R)-(+)-2,2'-bis-(diphenylphosphino)-1 ,1 '-binaphthyl]-(p-cymol)- ruthenium(l)-chlorid; CAS 145926-28-9), or Ru-Macho® (also known as Carbonylchlorohydrido{bis[2-(diphenylphosphinomethyl)ethyl]amino}ethyl]amino}ruthenium(ll); CAS 1295649-40-9), and in particular Carbonylchlorohydrido{bis[2- (diphenylphosphinomethyl)ethyl]amino}ethyl]amino}ruthenium(ll). In this connection, the catalyst such as the Carbonylchlorohydrido{bis[2- (diphenylphosphinomethyl)ethyl]amino}ethyl]amino}ruthenium(ll) is suitably present in an amount of about 0.5 to about 10 wt%, more preferably of about 1 to about 8 wt%, and in particular of about 3 to about 6 wt% such as about 5 wt%, based on the total amount of the compound of formula (2). These conditions are exemplarily suitable to hydrogenate the keto group (i.e. to obtain a compound of formula (1-2)).

[0277] In one embodiment, the compound of formula (2) is reacted with hydrogen in the presence of a reducing agent. The reducing agent and the compound of formula (2) have suitably a molar ratio of 1 :1 to 100:1 , preferably of 2:1 to 60:1 , more preferably of 5:1 to 50:1 , and in particular of 10:1 to 30:1 . A suitable reducing agent is Raney Nickel.

[0278] In one embodiment, reacting a compound of formula (2) with hydrogen is performed in a closed vessel under hydrogen pressure. Preferably, reacting a compound of formula (2) with hydrogen is performed at about 1 to about 60 bar hydrogen pressure, preferably about 5 to about 50 bar hydrogen pressure, and in particular at about 5 to about 20 bar hydrogen pressure, or at about 5 to about 10 bar hydrogen pressure, or at about 10 to about 20 bar hydrogen pressure, or at about 20 to about 30 bar, or at about 30 to about 50 bar, hydrogen pressure.

[0279] In one embodiment, reacting a compound of formula (2) with hydrogen is performed at a temperature of about -10 to about 50 °C, preferably of about -5 to about 40 °C such as of about -5 to about 25 °C, or of about 0 to about 20 °C, or of about 5 to about 15 °C, or of about 20 to about 40 °C.

[0280] In one embodiment, reacting a compound of formula (2) with hydrogen is stirred at about 700 rpm to about 1200 rpm so as to ensure sufficient hydrogen diffusion into the reaction mixture.

[0281] In one embodiment, reacting a compound of formula (2) with hydrogen is performed in a solvent. Suitable solvents include alcohols and ethers. In one embodiment, the solvent is selected from methanol, methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), 2-methyltetrahydrofuran (2Me- THF), ethylacetate, dioxane, and combinations thereof.

[0282] Reactions comprising a palladium catalyst suitably comprise an ether as solvent.

[0283] Reactions comprising a ruthenium catalyst suitably comprise an alcohol as solvent.

[0284] Reactions comprising a reducing agent suitably comprise an ether as solvent. In one embodiment, the compound of formula (1) is selected from preferably selected from

[0285]

[0286] 5 In one embodiment, the compound of formula (1) is selected from

[0287]

[0288]

[0289] In another embodiment, the compound of formula (1) is selected from

[0290] As aforementioned, the present invention further relates in a second aspect to a compound of formula (1-1) wherein

[0291] R1is -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12, -O-SiR13R14R15, or -NRBRc;

[0292] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0293] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0294] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0295] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0296] RAis H or optionally substituted C1-12 alkyl;

[0297] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl;

[0298] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl; and

[0299] X is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl or benzyl, that -NRA-C(O)-R11is not -NH-C(O)- NH2, and that RDis not tert-butyl.

[0300] In one embodiment, the present invention relates to a compound of formula (1-1) wherein

[0301] R1is -O-C(O)-R10, -O-C(O)-X-R12, -O-S(O)2-R12, or -NRBRc;

[0302] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0303] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted aryl; RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl; and

[0304] X is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl or benzyl.

[0305] Particular embodiments (e.g. regarding the moieties) are already above-outlined in the inventive process and shall hold for the inventive compounds, as well. In the following, particular preferred embodiments of the compounds are described in further detail. It is to be understood that each embodiment is relevant on its own as well as in combination with other embodiments.

[0306] In one embodiment,

[0307] R1is -O-C(O)-R10;

[0308] R10is halogen, -OH, ethyl, 1 -methylethyl, trifluoromethyl, para-methyl phenyl, para methylphenylketon, or -NRBRc; and

[0309] RBand Rcare independently H, optionally substituted C1-6 alkyl, phenyl, or benzyl.

[0310] In one embodiment,

[0311] R1is -NRA-C(O)-R11;

[0312] R11is -NRBRcor -ORD;

[0313] RAis H;

[0314] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H or optionally substituted C3-6 cycloalkyl;

[0315] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl.

[0316] In one embodiment,

[0317] R1is -O-C(O)-X-R12, O-S(O)2-R12, or -0-SiR13R14R15;

[0318] R12is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is optionally substituted C1-6 alkyl or optionally substituted C3-8 cycloalkyl, more preferably is optionally substituted C1-4 alkyl or optionally substituted C3-6 cycloalkyl;

[0319] R13, R14, and R15, are independently optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, more preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl.

[0320] In one embodiment,

[0321] R1is -O-C(O)-X-R12or O-S(O)2-R12; R12is optionally substituted C1-8 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted aryl, preferably is optionally substituted C1-6 alkyl or optionally substituted C3-8 cycloalkyl, more preferably is optionally substituted C1-4 alkyl or optionally substituted C3-6 cycloalkyl.

[0322] In one embodiment, the compound of formula (1-1) is selected from

[0323] preferably selected from

[0324] It will be obvious for a person skilled in the art that these embodiments only depict examples of a plurality of possibilities. Hence, the embodiments shown here should not be understood to form a limitation of these features and configurations. Any possible combination and configuration of the described features can be chosen according to the scope of the invention.

[0325] The present invention will be further illustrated by the following examples.

[0326] Examples General procedure A

[0327] The catalyst, the substrate and the solvent were charged under inert atmosphere (N2) in a 500 mL autoclave at a specific temperature. The autoclave was pressurized with H2 autoclave at a specific pressure and the mixture was stirred at 800 rpm. The reaction evolution was monitored following the H2 consume. After reaction completion the catalyst was removed by filtration and the filtrate was concentrated under reduced pressure at 30-35 °C to provide the crude product. Example 1 : 3-oxocyclobutyl benzoate

[0328] 3-oxocyclobutyl benzoate was synthetised following general procedure A. 3-oxocyclobut-1-en-1-yl benzoate (19.95 g, 106 mmol), Pd / C (5%, wet) (2.61 g), MTBE (181.53 g), 15 °C, 18 h; 3- oxocyclobutyl benzoate was isolated as a pale orange solid (18.50 g, 97 mmol, yield 96.7 %).

[0329] 1H-NMR: (400 MHz, CDCh) ppm 8.11 (m, 2H, HAr), 7.62 (m, 1 H, HAr), 7.51 (m, 2H, HAr), 5.52 (m, 1 H, CH), 3.60 (m, 2H, CH2), 3.37 (m, 2H, CH2);13C-NMR (100 MHz, CDCh) ppm 203.5 (1Cco), 166.2 (1Cco2), 133.31 (CAr), 129.5 (2CAr), 128.4 (2CAr), 60.6 (1 CCH), 54.6 (2CCH2).

[0330] Example 2: Methyl (3-oxocyclobutyl) carbonate

[0331] Methyl (3-oxocyclobutyl) carbonate was synthetised following general procedure A. Methyl (3- oxocyclobut-1-en-1-yl) carbonate (7.98 g, 56 mmol), Pd / C (5%, wet) (1.04 g), MTBE (156.84 g), 15 °C, 22 h; Methyl (3-oxocyclobutyl) carbonate was isolated as a yellow-orange oil (7.17 g, 50 mmol, yield 88.8 %).

[0332] 1H-NMR: (400 MHz, CDCh) ppm 5.23 (m, 1 H, CH), 3.81 (m, 3H, CH3), 3.45 (m, 2H, CH2), 3.27 (m, 2H, CH2);13C-NMR (100 MHz, CDCh) ppm 202.5 (1Cco), 155.0 (1Cco3), 62.9 (1 CCH), 54.8 (1 CCH3), 54.3 (2CCH2).

[0333] Example 3: Synthesis of 3-oxocyclobutyl phenyl carbonate

[0334] 3-Oxocyclobutyl phenyl carbonate was synthetised following general procedure A. 3-Oxocyclobut-1- en-1-yl phenyl carbonate (22.16 g, 109 mmol), Pd / C (5%, wet) (2.52 g), MTBE (240.41 g), 15 °C, 21 h; 3-Oxocyclobutyl phenyl carbonate was isolated as a pale orange-pinky solid (19.38 g, 94 mmol, yield 86.6 %).

[0335] 1H-NMR: (400 MHz, CDCh) ppm 7.47 (m, 2H, HAr),7.31 (m, 1 H, HAr), 7.28 (m, 2H, HAr), 5.37 (m, 1 H, CH), 3.55 (m, 3H, CH3), 3.43 (m, 2H, CH2);13C-NMR (100 MHz, CDCh) ppm 202.5 (1Cco), 156.0 (1Cco3), 129.4 (2CAr), 126.1 (1 CAr), 120.7 (2CAr), 69.7 (1 CCH), 54.2 (4CCH2).

[0336] Example 4: Synthesis of 3-hydroxycyclobutyl benzoate

[0337] 3-Hydroxycyclobutyl benzoate was synthetised following general procedure A. 3-Oxocyclobutyl benzoate (5.07 g, 0.03 mol), Ru / C (5%, dry) (1 .07 g), MTBE (140.09 g), 25 °C, 25 bar H2, 73 h; crude product isolated as a yellowish oil (5.19 g, mixture of isomers cis / trans).

[0338] 1H-NMR: (400 MHz, CDCh) ppm 8.09-8.11 (2H, HAr), 7.58-7.62 (1 H, m, HAr), 7.48-7.50 (2H, m, HAr), 4.83-4.92 (1 H, m, CH-O), 4.09-4.16 (1 H, m, CH-OH), 2.97-3.04 (2H, m, CH2), 2.23-2.31 (2H, m, CH2).

[0339] Example 5: Synthesis of 3-hydroxycyclobutyl methyl carbonate 3-Hydroxycyclobutyl methyl carbonate was synthetised following general procedure A. Methyl (3- oxocyclobutyl) carbonate (6.40 g, 0.04 mol), Ru / C (5%, dry) (1 .04 g), MTBE (161 .14 g), 15 °C, 15 bar H2, 54 h; crude product isolated as a colourless oil (6.61 g, mixture of isomers cis / trans).

[0340] 1H-NMR: (400 MHz, CDCh) ppm 4.53-4.62 (1 H, m, CH-O), 3.96-4.03 (1 H, m, CH-OH), 3.80 (3H, s, CH3), 2.84-2.92 (2H, m, CH2), 2.08-2.16 (2H, m, CH2). carbonate

[0341] 3-Hydroxycyclobutyl phenyl carbonate was synthetised following general procedure A. 3- Oxocyclobutyl phenyl carbonate (6.10 g, 0.03mol), Ru / C (5%, dry) (1.09 g), MTBE (150.76 g), 25 °C, 25 bar H2, 42 h; crude product isolated as a pale yellowish oil (6.07 g, mixture of isomers cis / trans).1H-NMR: (400 MHz, CDCh) ppm 7.24-7.29 (2H, m, HAr), 7.10-7.14 (1 H, m, HAr), 7.04-7.09 (2H, m, HAr), 4.47-4.55 (1 H, m, CH-O), 3.81-3.88 (1 H, m, CH-OH), 2.72-2.79 (2H, m, CH2), 2.03-2.10 (2H, m, CH2).

[0342] Example 7: Synthesis of cyclobutanon

[0343] 5,8-dithiaspiro[3.4]octan-2-one (2.17 g, 0.14 mol, 1 eq.), Raney-Nickle (0.26 mol, 19 eq.) and ethanol (168 g) were heated to reflux for 3h. Crude Cyclobutanone (1 .38 g, 0.02 mol, 14%) was obtained by distillation.1H-NMR: (400 MHz, CDCh) ppm 3.27 (m, 4H, CH2), 2.42 (s, 2H, CH2). Example 8: Synthesis of cyclobutane-1 ,3-diol.

[0344] Ru-MACHO

[0345] Cyclobutane-1 ,3-dione (53 g, 0.20 mol, 1 eq.), Ru-MACHO (0.1 g, 0.2 mmol, 0.1 mol%) and fBuONa (1.9 g, 0.02 mol, 0.1 eq.) were mixed in a hydrogenation reactor. The pressure was increased to 40 bar and the temperature was increased to 40°C for 20h. Cyclobutane-1 ,3-diol could be isolated quantitatively as a crude product.1H-NMR: (400 MHz, CDCI3) ppm 4.22 (2H, m, CH), 2.56 (4H, m, CH2).

[0346] The invention further relates to the following items:

[0347] 1 . A process for the preparation of a compound of formula (1) wherein

[0348] R1is H, -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12,-O-SiR13R14R15, or -NRBRc;

[0349] R2and R3represent =O or

[0350] R2is -OH or -NRBRcand R3is H;

[0351] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;

[0352] R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0353] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0354] R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; RAis H or optionally substituted C1-12 alkyl;

[0355] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0356] RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and

[0357] X is O, S, or NH; the process comprising reacting a compound of formula (2) wherein

[0358] RX1and RX4represent =O or -S-C2-6 alkylene-S- and RX5is H, or

[0359] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;

[0360] RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;

[0361] RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD;

[0362] RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0363] RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0364] RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;

[0365] RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; and

[0366] RXE(+)is a cation; with hydrogen. 2. The process according to item 1 , wherein the compound of formula (2) is a compound of formula (2-1) or a compound of formula (2-2) wherein

[0367] RX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15or -O(_)RXE(+).

[0368] 3. The process according to item 2, wherein

[0369] R1is -O-C(O)-R10;

[0370] R2and R3represent =O;

[0371] R10is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, phenyl, or -NRBRC;

[0372] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl;

[0373] RX1is -O-C(O)-RX1°; and RX1° is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, tert-butyl, phenyl, or -NRBRc;

[0374] RXBand Rxcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl.

[0375] 4. The process according to item 2, wherein

[0376] R1is -NRA-C(O)-R11;

[0377] R2and R3represent =O;

[0378] R11is -NRBRcor -ORD;

[0379] RAis H;

[0380] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H or optionally substituted C3-6 cycloalkyl;

[0381] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl, RX1is -NRA-C(O)-RX11;

[0382] RX11is -NRXBRxcor -ORXD;

[0383] RXBand Rxcare independently selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H, optionally substituted C3-6 cycloalkyl or optionally substituted C3-8 cycloalkenyl;

[0384] RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted

[0385] C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, phenyl, or benzyl.

[0386] 5. The process according to item 2, wherein

[0387] R1is -O-C(O)-X-R12, O-S(O)2-R12, or -0-SiR13R14R15;

[0388] R12is optionally substituted C1-6 alkyl or optionally substituted C3-8 cycloalkyl, preferably is optionally substituted C1-4 alkyl or optionally substituted C3-6 cycloalkyl;

[0389] R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl;

[0390] RX1is -O-C(O)-X-Rx12, O-S(O)2-RX12, or -0-SiRx13Rx14Rx15;

[0391] RX12is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted C3-8 cycloalkenyl, preferably is optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, or optionally substituted C3-6 cycloalkenyl;

[0392] R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl; and

[0393] X is O.

[0394] 6. The process according to item 2, wherein

[0395] R1is -OH, -O-C(O)-R10, or -NRBRc;

[0396] R2and R3represent =O or

[0397] R2is -OH or -NRBRcand R3is H; R10is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl;

[0398] RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl;

[0399] RX1is -O-C(O)-RX1° or -0( )RXE(+);

[0400] RX1° is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl; RXBand Rxcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, optionally substituted phenyl, optionally substituted benzyl; and RXE(+)is an amine cation.

[0401] 7. The process according to item 6, wherein the amine cation is a compound of formula (4)

[0402] [NR20R21R22R23](+)(4) wherein

[0403] R20and R21are independently selected from the group consisting of optionally substituted Ci-Cw- alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or R20and R21together with the N atom to which they are bonded form a 5- to 12-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from N, O, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RF, preferably are independently selected from the group consisting of optionally substituted Ci-Ce-alkyl and optionally substituted C3-6 cycloalkyl;

[0404] R22is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl;

[0405] R23is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl; and

[0406] RFis halogen, -OH, or optionally substituted Ci-Cw-alkyl.

[0407] 8. The process according to item 1 , wherein

[0408] RX1and RX4represent =O or-S-C2-6 alkylene-S-, preferably =O or -S-CH2-CH2-S-; and RX5is H.

[0409] 9. The process according to any one of items 1 to 8, wherein the compound of formula (2) is reacted with hydrogen in the presence of a catalyst, preferably wherein the catalyst is present in an amount of 0.5 to 10 wt%, more preferably of 1 to 8 wt%, and in particular of 3 to 6 wt%, based on the total amount of the compound of formula (2).

[0410] 10. The process according to item 9, wherein the catalyst is a palladium catalyst, preferably Pd / C; or wherein the catalyst is a ruthenium catalyst, preferably Ru / C or Carbonylchlorohydrido{bis[2-(diphenylphosphinomethyl)ethyl]amino}ethyl]amino}ruthenium(ll).

[0411] 11 . The process according to any one of items 1 to 10, wherein the compound of formula (2) is reacted with hydrogen in the presence of a reducing agent, preferably wherein the reducing agent is Raney Nickel and / or wherein the reducing agent and the compound of formula (2) have a molar ratio of 1 :1 to 100:1 , preferably of 2:1 to 60:1 , and in particular of 5:1 to 50:1.

[0412] 12. The process according to any one of items 1 to 10, wherein reacting the compound of formula (2) with hydrogen is performed at a temperature of about -10 to about 50 °C, preferably of about -5 to about 40 °C, more preferably of about -5 to about 25 °C, still more preferably of about 0 to about 20 °C, and in particular of about 5 to about 15 °C, and / or wherein reacting a compound of formula (2) with hydrogen is performed at about 1 to about 60 bar hydrogen pressure, preferably about 5 to about 50 bar hydrogen pressure, and in particular at about 5 to about 20 bar hydrogen pressure, or at about 5 to about 10 bar hydrogen pressure, or at about 10 to about 20 bar hydrogen pressure, or at about 30 to about 50 bar, hydrogen pressure.

[0413] 13. The process according to any one of items 1 to 12, further comprising a solvent, preferably selected from the group consisting of methanol, methyl tert-butyl ether, tetrahydrofuran (THF), 2- methyltetrahydrofuran (2Me-THF), ethylacetate, dioxane, and combinations thereof.

[0414] 14. The process according to any one of items 1 to 13, wherein the compound of formula (1) is selected from

[0415] wherein

[0416] R1is -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12, -O-SiR13R14R15, or -NRBRc;

[0417] R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc; R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;

[0418] R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;

[0419] RAis H or optionally substituted C1-12 alkyl;

[0420] RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; and X is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl, or benzyl, that -NRA-C(O)-R11is not -NH-C(O)- NH2, and that RDis not tert-butyl.

Claims

Claims1 . A process for the preparation of a compound of formula (1)whereinR1is -OH, -O-C(O)-R10, -NRA-C(O)-R11, -O-C(O)-X-R12, -O-S(O)2-R12,-O-SiR13R14R15, or -NRBRc;R2and R3represent =O orR2is -OH or -NRBRcand R3is H;R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;R11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, -NRBRC, or -ORD;R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;R13, R14, and R15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;RAis H or optionally substituted C1-12 alkyl;RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl;RDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; andX is O, S, or NH; the process comprising reacting a compound of formula (2)whereinRX1and RX4represent =O and RX5is H, orRX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O( )RXE(+)and RX4and RX5together form a bond or RX4and RX5are both H;RX1° is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRXBRXC;RX11is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, -NRXBRXC, or -ORXD;RX12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;RXI3, RX14, and RX15, are independently optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl;RXBand Rxcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl;RXDis optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl; andRXE(+)is a cation; with hydrogen, wherein the compound of formula (2) is reacted with hydrogen in the presence of a catalyst, and wherein reacting the compound of formula (2) with hydrogen is performed at about 5 to about 60 bar hydrogen pressure.

2. The process according to claim 1 , wherein the compound of formula (2) is a compound of formula (2-1)preferably wherein the compound of formula (1) is a compound of formula (1-1)cording to claim 1 , wherein the compound of formula (2) is a compound of(2-2), preferably wherein the compound of formula (1) is a compound of formula (1-2)(1-2).

4. The process according to claim 1 , wherein the compound of formula (2) is a compound of formula (2-1) or a compound of formula (2-2)whereinRX1is -O-C(O)-RX1°, -NRA-C(O)-RX11, -O-C(O)-X-Rx12, -O-S(O)2-RX12, -O-SiRx13Rx14Rx15, or -O(_)RXE(+).

5. The process according to claim 4, whereinR1is -O-C(O)-R10;R2and R3represent =O;R10is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionallysubstituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, phenyl, or -NRBRC;RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl;RX1is -O-C(O)-RX1°; and RX1° is chlorine, -OH, optionally substituted C2-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, optionally substituted benzyl, or -NRBRc, preferably is chlorine, -OH, tert-butyl, phenyl, or -NRBRc;RXBand Rxcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently H, phenyl, or benzyl.

6. The process according to claim 4, whereinR1is -NRA-C(O)-R11;R2and R3represent =O;R11is -NRBRcor -ORD;RAis H;RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H or optionally substituted C3-6 cycloalkyl;RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, phenyl, or benzyl, RX1is -NRA-C(O)-RX11;RX11is -NRXBRxcor -ORXD;RXBand Rxcare independently selected from H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably are independently H, optionally substituted C3-6 cycloalkyl or optionally substituted C3-8 cycloalkenyl;RDis optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substitutedC3-8 cycloalkenyl, optionally substituted phenyl, or optionally substituted benzyl, preferably optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, phenyl, or benzyl.

7. The process according to claim 4, whereinR1is -O-C(O)-X-R12, O-S(O)2-R12, or -0-SiR13R14R15;R12is optionally substituted C1-6 alkyl or optionally substituted C3-8 cycloalkyl, preferably is optionally substituted C1-4 alkyl or optionally substituted C3-6 cycloalkyl;R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl;RX1is -O-C(O)-X-Rx12, O-S(O)2-RX12, or -0-SiRx13Rx14Rx15;RX12is optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted C3-8 cycloalkenyl, preferably is optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, or optionally substituted C3-6 cycloalkenyl;R13, R14, and R15, are independently optionally substituted C1-6 alkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-6 alkyl, phenyl, or benzyl; and X is O.

8. The process according to claim 4, wherein R1is -OH, -O-C(O)-R10, or -NRBRc;R2and R3represent =O orR2is -OH or -NRBRcand R3is H;R10is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl;RBand Rcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted phenyl, or optionally substituted benzyl;RX1is -O-C(O)-RX1° or -0( )RXE(+);RX1° is optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, or optionally substituted phenyl, preferably is optionally substituted C2-6 alkyl;RXBand Rxcare independently H, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, preferably are independently optionally substituted C1-4 alkyl, optionally substituted C3-6 cycloalkyl, optionally substituted C3-6 cycloalkenyl, optionally substituted phenyl, optionally substituted benzyl; and RXE(+)is an amine cation.

9. The process according to claim 8, wherein the amine cation is a compound of formula (4)[NR20R21R22R23](+)(4) whereinR20and R21are independently selected from the group consisting of optionally substituted Ci-Cw- alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, optionally substituted alkylaryl, or R20and R21together with the N atom to which they are bonded form a 5- to 12-membered saturated, partially or fully unsaturated, or aromatic heterocyclic ring, wherein said heterocyclic ring comprises one or more, same or different heteroatoms selected from N, O, or S, wherein said N- and / or S-atoms are independently oxidized or non-oxidized, and wherein each substitutable carbon or heteroatom in the heterocyclic ring is independently unsubstituted or substituted with one or more, same or different substituents RF, preferably are independently selected from the group consisting of optionally substituted Ci-Ce-alkyl and optionally substituted C3-6 cycloalkyl;R22is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl;R23is H, optionally substituted Ci-Cw-alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted aryl, or optionally substituted alkylaryl, preferably is H or optionally substituted Ci-Ce-alkyl; andRFis halogen, -OH, or optionally substituted Ci-Cw-alkyl.

10. The process according to any one of claims 1 to 9, wherein the catalyst is present in an amount of 0.5 to 10 wt%, preferably of 1 to 8 wt%, and in particular of 3 to 6 wt%, based on the total amount of the compound of formula (2).11 . The process according to claim 10, wherein the catalyst is a palladium catalyst, preferably Pd / C; or wherein the catalyst is a ruthenium catalyst, preferably Ru / C or Carbonylchlorohydrido{bis[2-(diphenylphosphinomethyl)ethyl]amino}ethyl]amino}ruthenium(ll).

12. The process according to any one of claims 1 to 10, wherein reacting the compound of formula (2) with hydrogen is performed at a temperature of about -10 to about 50 °C, preferably of about -5 to about 40 °C, more preferably of about -5 to about 25 °C, still more preferably of about 0 to about 20 °C, and in particular of about 5 to about 15 °C, and / or wherein reacting the compound of formula (2) with hydrogen is performed at about 5 to about 50 bar hydrogen pressure, and in particular at about 5 to about 20 bar hydrogen pressure, or at about 5 to about 10 bar hydrogenpressure, or at about 10 to about 20 bar hydrogen pressure, or at about 30 to about 50 bar, hydrogen pressure.

13. The process according to any one of claims 1 to 12, further comprising a solvent, preferably selected from the group consisting of methanol, methyl tert-butyl ether, tetrahydrofuran (THF), 2- methyltetrahydrofuran (2Me-THF), ethylacetate, dioxane, and combinations thereof.

14. The process according to any one of claims 1 to 13, wherein the compound of formula (1) is selected from15. A compound of formula (1-1)whereinR1is -O-C(O)-R10,-O-C(O)-X-R12, -O-S(O)2-R12, or -NRBRc; R10is halogen, -OH, optionally substituted C2-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, or -NRBRc;R12is optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, or optionally substituted aryl;RBand Rcare independently H, optionally substituted C1-12 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted aryl, or optionally substituted alkylaryl; andX is O, S, or NH; with the proviso that R10is not tert-butyl, phenyl, or benzyl.

Citation Information

Patent Citations

  • 3-Acetoxy-cyclo:butanone prodn.

    CH596132A5

  • Preparation method of 3-oxocyclobutyl ammonia

    CN106631843A

  • Bicyclic heteroaromatic ring derivative

    EP3842439A1

  • Thiazole derivatives

    US20030078252A1

  • Catalyst and method for hydrogenation of 1,3-cyclobutanediketone compound

    US20170334815A1